Sphere Fluidics Enhances Capabilities of its Cyto-Mine System
The new design improves system performance, reliability, and stability, while an update to the software provides a better user experience, reduces user-instrument interaction, and allows for more robust data analysis.
Sphere Fluidics has enhanced the capabilities and performance of its Cyto-Mine System, an automated platform that combines single cell screening, sorting, dispensing, imaging, and clone verification.
The new design improves system performance, reliability, and stability, while an update to the software provides a better user experience, reduces user-instrument interaction, and allows for more robust data analysis, Sphere Fluidics said in a May 17, 2021 company press release. The updated instrument also works to simplify antibody discovery, cell-line development, cell therapy, and synthetic biology workflows.
“The new design is the culmination of 18 months' hard work by our R&D team. Due to the deployment of these latest improvements, researchers are now able to perform even faster selective screening of single cells to find rare lead candidates,” said Marian Rehak, vice-president of Research and Development at Sphere Fluidics, in the press release. “Although, principally designed for antibody discovery and cell line development, the platform is very flexible and has now been demonstrated to be useful in a wide variety of application areas.”
“The new Cyto-Mine design not only unlocks increased functionality for scientists but is also faster to manufacture, commission, and service,” added Rob Treanor, operations director at Sphere Fluidics, in the press release. “A new user can learn how to run our user-friendly software within a single working day. We are helping our users to simplify their workflows with the added operational benefit of enhancing our service and support capacity.”
Source: Sphere Fluidics
